About GenOway
GenOway is a company based in Lyon (France) founded in 1999.. GenOway has raised $11.55 million across 5 funding rounds from investors including Siparex, European Union and Eurostars. The company has 143 employees as of December 31, 2024. GenOway has completed 1 acquisition, including Axenis. GenOway offers products and services including Humanized Mice, Cell Lines, Knockout Models, and Customized Models. GenOway operates in a competitive market with competitors including Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Biocytogen, among others.
- Headquarter Lyon, France
- Employees 143 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Genoway Sa
-
Annual Revenue
$22.92 M (USD)10.04as on Dec 31, 2024
-
Net Profit
$1.9 M (USD)16.79as on Dec 31, 2024
-
EBITDA
$110.77 K (USD)111.08as on Dec 31, 2024
-
Total Equity Funding
$11.55 M (USD)
in 5 rounds
-
Latest Funding Round
$280.38 K (USD), Grant
Jan 01, 2020
-
Investors
Siparex
& 5 more
-
Employee Count
143
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of GenOway
GenOway is a publicly listed company on the EURONEXT with ticker symbol ALGEN in France, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of GenOway
GenOway offers a comprehensive portfolio of products and services, including Humanized Mice, Cell Lines, Knockout Models, and Customized Models. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Genetically modified mice for in vivo efficacy and safety testing
Modified cell lines for tumor growth and mechanistic studies
Mice and rats with targeted gene knockouts for research purposes
Bespoke genetically modified models for specific scientific questions
Unlock access to complete
Funding Insights of GenOway
GenOway has successfully raised a total of $11.55M across 5 strategic funding rounds. The most recent funding activity was a Grant round of $280.38 thousand completed in January 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Grant — $280,382
-
First Round
First Round
(30 Apr 2003)
- Investors Count 6
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2020 | Amount | Grant - GenOway | Valuation |
investors |
|
| Feb, 2016 | Amount | Grant - GenOway | Valuation |
investors |
|
| Mar, 2014 | Amount | Grant - GenOway | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in GenOway
GenOway has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include Siparex, European Union and Eurostars. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity investments are focused on growth stage companies.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by GenOway
GenOway has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Axenis. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Chimeric in-vivo mouse models for biomedical research are developed.
|
2010 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - GenOway
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Genoway Comparisons
Competitors of GenOway
GenOway operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Biocytogen, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| domain | founded_year | HQ Location |
Biomanufacturing technologies are supplied for biopharma antibody and vaccine production.
|
|
| domain | founded_year | HQ Location |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| domain | founded_year | HQ Location |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| domain | founded_year | HQ Location |
Integrated solutions for next-generation antibody drug development are provided.
|
|
| domain | founded_year | HQ Location |
RNA-editing technologies are provided for precision medicine applications.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Genoway
Frequently Asked Questions about GenOway
When was GenOway founded?
GenOway was founded in 1999 and raised its 1st funding round 4 years after it was founded.
Where is GenOway located?
GenOway is headquartered in Lyon, France. It is registered at Lyon, Auvergne-rhone-alpes, France.
Is GenOway a funded company?
GenOway is a funded company, having raised a total of $11.55M across 5 funding rounds to date. The company's 1st funding round was a Grant of $21.43K, raised on Apr 30, 2003.
How many employees does GenOway have?
As of Dec 31, 2024, the latest employee count at GenOway is 143.
What is the annual revenue of GenOway?
Annual revenue of GenOway is $22.92M as on Dec 31, 2024.
What does GenOway do?
GenOway was founded in 1999 and is based in Lyon, France. Operations center on the biotechnology sector, where transgenic mouse and rat models, along with customized cell lines, are created using techniques such as homologous recombination, CRISPRCas, FLEX, TET, and IRES Rosa 26Hprt. Knockout genes and point mutations are incorporated to address needs in neuroscience, immunology, metabolism, cardiovascular disorders, and cancer research.
Who are the top competitors of GenOway?
GenOway's top competitors include Sutro Biopharma, Biocytogen and Avidity Biosciences.
What products or services does GenOway offer?
GenOway offers Humanized Mice, Cell Lines, Knockout Models, and Customized Models.
Is GenOway publicly traded?
Yes, GenOway is publicly traded on EURONEXT under the ticker symbol ALGEN.
How many acquisitions has GenOway made?
GenOway has made 1 acquisition, including Axenis.
Who are GenOway's investors?
GenOway has 6 investors. Key investors include Siparex, European Union, Eurostars, CDC Entreprises Innovation, and Dassault Developpement.
What is GenOway's ticker symbol?
The ticker symbol of GenOway is ALGEN on EURONEXT.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.